Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 20, 2024Molecular OncologyOpen Access

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYasmin YuMBMadhumita BogdanMNMuhammad Zaeem Noman

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yu et al. (2024) studied this question.

synapsesocial.com/papers/68e732bfb6db6435876abe25https://doi.org/10.1002/1878-0261.13619
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy2024
  2. 2Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS342024 · 1 citations
  3. 3VPS34-IN1 inhibits cap-mediated translation and synergizes with STING to drive type-I IFN expression in human plasmacytoid DCs2024 · 1 citations
  4. 4Targeting VCP enhances colorectal cancer therapy through STING stabilization2025
  5. 5Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth2026 · 1 citations